EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles

Georgios Mangioris iD, Thorvardur R Halfdanarson, Vanda A Lennon, Bryce K Chang iD, Divyanshu Dubey, P James B Dyck, Eoin P Flanagan iD, Andrew McKeon, John R Mills, Sean J Pittock iD, Anastasia Zekeridou iD

European Journal of Neurology · 2024-06 · 31 (6)

DOI: 10.1111/ene.16273 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2024-03-11. Written by Georgios Mangioris and 10 co-authors. Institution: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Autoantibodies, Neuroendocrine Tumors. Cited 3 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NINDS NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and purpose Paraneoplastic neurological autoimmunity is well described with small‐cell lung cancer, but information is limited for other neuroendocrine neoplasms (NENs).

Methods

Adult patients with histopathologically confirmed non‐pulmonary NENs, neurological autoimmunity within 5 years of NEN diagnosis, and neural antibody testing performed at the Mayo Clinic Neuroimmunology Laboratory (January 2008 to March 2023) were retrospectively identified. Control sera were available from patients with NENs without neurological autoimmunity (116).

Results

Thirty‐four patients were identified (median age 68 years, range 31–87). The most common primary tumor sites were pancreas (nine), skin (Merkel cell, eight), small bowel/duodenum (seven), and unknown (seven). Five patients received immune checkpoint inhibitor (ICI) therapy before symptom onset; symptoms preceded cancer diagnosis in 62.1% of non‐ICI‐treated patients. The most frequent neurological phenotypes (non‐ICI‐treated) were movement disorders (12; cerebellar ataxia in 10), dysautonomia (six), peripheral neuropathy (eight), encephalitis (four), and neuromuscular junction disorders (four). Neural antibodies were detected in 55.9% of patients studied (most common specificities: P/Q‐type voltage‐gated calcium channel [seven], muscle‐type acetylcholine receptor [three], anti‐neuronal nuclear antibody type 1 [three], and neuronal intermediate filaments [two]), but in only 6.9% of controls. Amongst patients receiving cancer or immunosuppressive therapy, 51.6% had partial or complete recovery. Outcomes were unfavorable in 48.3% (non‐ICI‐treated) and neural autoantibody positivity was associated with poor neurological outcome.

Discussion

Neurological autoimmunity associated with non‐pulmonary NENs is often multifocal and can be treatment responsive, underscoring the importance of rapid recognition and early treatment.

Subjects

MeSH terms (MEDLINE)

AutoantibodiesNeuroendocrine TumorsHumansMaleFemaleAgedMiddle AgedAdultAged, 80 and overRetrospective StudiesAutoimmunityParaneoplastic Syndromes, Nervous SystemAutoimmune Diseases of the Nervous System

Author keywords

carcinoidcerebellar ataxiaencephalitismyasthenia gravisparaneoplastic syndromes

Substances

Autoantibodies

Authors and institutions

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Georgios Mangioris, Bryce K Chang, Eoin P Flanagan, Sean J Pittock, Anastasia Zekeridou

Funding

  • NINDS NIH HHS

Cite

APA

Mangioris, G., Halfdanarson, T. R., Lennon, V. A., Chang, B. K., Dubey, D., Dyck, P. J. B., Flanagan, E. P., McKeon, A., Mills, J. R., Pittock, S. J., & Zekeridou, A. (2024). Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles. European Journal of Neurology, 31(6). https://doi.org/10.1111/ene.16273

Vancouver

Mangioris G, Halfdanarson TR, Lennon VA, Chang BK, Dubey D, Dyck PJB, et al. Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles. European Journal of Neurology. 2024;31(6). doi:10.1111/ene.16273

BibTeX
@article{Mangioris2024,
  author = {Mangioris, Georgios and Halfdanarson, Thorvardur R and Lennon, Vanda A and Chang, Bryce K and Dubey, Divyanshu and Dyck, P James B and Flanagan, Eoin P and McKeon, Andrew and Mills, John R and Pittock, Sean J and Zekeridou, Anastasia},
  title = {Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {6},
  doi = {10.1111/ene.16273}
}
Start for free →